Rigel Pharmaceuticals (RIGL) Revenue Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.20% |
| Dec 31, 2025 | 30.49% |
| Sep 30, 2025 | 30.45% |
| Jun 30, 2025 | 44.71% |
| Mar 31, 2025 | -0.89% |
| Dec 31, 2024 | 30.19% |
| Sep 30, 2024 | 21.54% |
| Jun 30, 2024 | 28.77% |
| Mar 31, 2024 | 18.53% |
| Dec 31, 2023 | -1.12% |
| Sep 30, 2023 | 42.05% |
| Jun 30, 2023 | 71.98% |
| Dec 31, 2022 | 68.13% |
| Sep 30, 2022 | 90.21% |
| Mar 31, 2022 | 36.10% |
| Dec 31, 2021 | 46.74% |
| Sep 30, 2021 | 41.78% |
| Jun 30, 2021 | 25.04% |
| Mar 31, 2021 | 74.35% |
| Dec 31, 2020 | 16.66% |
| Sep 30, 2020 | 7.19% |
| Jun 30, 2020 | 25.32% |
| Mar 31, 2020 | 91.27% |
| Dec 31, 2018 | 45.78% |
| Jun 30, 2018 | 5.00% |
| Mar 31, 2017 | 36.73% |
| Sep 30, 2016 | -2.90% |
| Jun 30, 2016 | 85.15% |
| Sep 30, 2015 | -29.05% |
| Jun 30, 2015 | -36.31% |